Cardiff Oncology to Participate in Fireside Chat at the Virtual BTIG Biotechnology Conference
Cardiff Oncology (Nasdaq: CRDF) announced participation in the BTIG Biotechnology Virtual Conference on August 10-11, 2020. CEO Dr. Mark Erlander will discuss the advancements and challenges in KRAS inhibition for solid tumors, highlighting onvansertib, a first-in-class Polo-like Kinase 1 (PLK1) inhibitor. The discussion aims to address the potential of onvansertib in treating KRAS-mutated colorectal cancer, a historically challenging area. Attendees can join the presentation through the conference portal.
- None.
- None.
SAN DIEGO, Aug. 4, 2020 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, castration-resistant prostate cancer and leukemia, today announced that the Company will participate in the BTIG Biotechnology Virtual Conference taking place August 10-11, 2020.
Presenter: Dr. Mark Erlander, chief executive officer
Topic: KRAS Inhibition in Solid Tumors – Material Advancements and Continuing Challenges
Date: Monday, August 10, 2020
Time: 12:30 p.m. PT / 2:30 p.m. CT / 3:30 p.m. ET.
The discussion with Cardiff Oncology will focus on the Company's oral and highly selective Polo-like Kinase 1 (PLK1) inhibitor, onvansertib, and its promise as a new therapeutic option in KRAS-mutated metastatic colorectal cancer, which has historically been a very challenging indication to effectively target and treat.
Conference attendees are welcome to join the fireside chat via the conference portal.
About Cardiff Oncology, Inc.
Cardiff Oncology (formerly Trovagene, Inc.) is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need. Our goal is to overcome resistance, improve response to treatment and increase overall survival. We are developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Our clinical development programs incorporate tumor genomics and biomarker technology to enable assessment of patient response to treatment. We have three ongoing clinical programs that are demonstrating the safety and efficacy of onvansertib: a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin® in KRAS-mutated metastatic colorectal cancer (mCRC); a Phase 2 study of onvansertib in combination with Zytiga® (abiraterone)/prednisone in metastatic castration-resistant prostate cancer (mCRPC); and a Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia (AML). For more information, please visit https://cardiffoncology.com/.
Cardiff Oncology Contact:
Vicki Kelemen
EVP and Chief Operating Officer
858-952-7652
vkelemen@cardiffoncology.com
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Karen O'Shea, Ph.D.
LifeSci Communications
929-469-3860
koshea@lifescicomms.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/cardiff-oncology-to-participate-in-fireside-chat-at-the-virtual-btig-biotechnology-conference-301105428.html
SOURCE Cardiff Oncology, Inc.
FAQ
What is the date of Cardiff Oncology's presentation at the BTIG Biotechnology Conference?
Who is presenting on behalf of Cardiff Oncology at the conference?
What topic will Cardiff Oncology discuss during the conference?
What is onvansertib and its significance in cancer treatment?
How can attendees access Cardiff Oncology's presentation?
